Boiron SA (BOI.PA)
- Previous Close
34.15 - Open
34.00 - Bid --
- Ask --
- Day's Range
33.85 - 34.00 - 52 Week Range
32.48 - 56.50 - Volume
806 - Avg. Volume
3,661 - Market Cap (intraday)
591.186M - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
16.53 - EPS (TTM)
2.06 - Earnings Date May 16, 2024 - May 17, 2024
- Forward Dividend & Yield 1.35 (3.95%)
- Ex-Dividend Date Jun 3, 2024
- 1y Target Est
39.60
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
www.boiron.fr2,501
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: BOI.PA
Performance Overview: BOI.PA
Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BOI.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BOI.PA
Valuation Measures
Market Cap
600.73M
Enterprise Value
540.39M
Trailing P/E
16.80
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.22
Price/Book (mrq)
1.53
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
7.26%
Return on Assets (ttm)
4.14%
Return on Equity (ttm)
7.15%
Revenue (ttm)
493.25M
Net Income Avi to Common (ttm)
35.83M
Diluted EPS (ttm)
2.06
Balance Sheet and Cash Flow
Total Cash (mrq)
74.04M
Total Debt/Equity (mrq)
3.50%
Levered Free Cash Flow (ttm)
28.55M
Research Analysis: BOI.PA
Company Insights: BOI.PA
BOI.PA does not have Company Insights